Search results
Results from the WOW.Com Content Network
Volasertib (also known as BI 6727) is an experimental small molecule inhibitor of the PLK1 (polo-like kinase 1) protein being developed by Boehringer Ingelheim for use as an anti-cancer agent. Volasertib is the second in a novel class of drugs called dihydropteridinone derivatives. [1]
C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies , and the largest private one.
Ofev was developed by Boehringer Ingelheim. It received U.S. Food and Drug Administration (FDA) approval for use for idiopathic pulmonary fibrosis in 2014 – one of only two drugs available for treating IPF – and numerous studies since have demonstrated its effectiveness in slowing the progressive, terminal lung disease. [8]
Pages in category "Drugs developed by Boehringer Ingelheim" The following 30 pages are in this category, out of 30 total. This list may not reflect recent changes. A.
breast cancer: Herceptin 6981 7013 9 bevacizumab: colon cancer: Avastin 6847 6686 10 rituximab: non-Hodgkin's lymphoma: Rituxan, MabThera 6750 7298 11 rivaroxaban: anticoagulant: Xarelto 6589 6234 12 aflibercept: Eylea 6551 5830 13 infliximab: Remicade 5908 7152 14 Pneumococcal conjugate vaccine: Prevnar 13 Prevenar 13 5802 5601 15 ustekinumab ...
Boehringer is committed to providing breakthrough therapies for cancer patients, and we look forward to advancing the zongertinib clinical program.” Zongertinib was generally well tolerated for 120 mg and 240 mg, with no deaths attributed to treatment and a low incidence of adverse events leading to dose reductions (11%) and discontinuation (3%).
Phase II results for breast cancer that over-expresses the protein human epidermal growth factor receptor 2 (Her2-positive breast cancer) were described as promising by the authors, with 19 of 41 patients achieving benefit from afatinib. [10] Double-blind Phase III trials are under way to confirm or refute this finding. Her2-negative breast ...
The drug, which was designated as an orphan medical product by the European Medicines Agency in March 2005, was developed by TeGenero, tested by Parexel and manufactured by Boehringer Ingelheim. [ 8 ] [ 9 ] TeGenero announced the first elucidation of the molecular structure of CD28 almost exactly one year prior to commencement of the TGN1412 ...